A. Chan

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial

A. Chien, N. Iannotti, C. Barcenas, 2020 .

Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer.

R Snyder, J F Forbes, J. Forbes, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

BCIRG 006: Docetaxel and trastuzumab-based regimens improve DFS and OS over AC-T in node positive and high risk node negative HER2 positive early breast cancer patients: Quality of life (QOL) at 36 months follow-up

N. Robert, W. Eiermann, H. Au, 2007 .

LBA8A PHASE III RANDOMIZED, DOUBLE-BLIND, TRIAL COMPARING SORAFENIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC HER2-NEGATIVE BREAST CANCER (RESILIENCE)

J. Bergh, C. Hudis, W. Gradishar, 2014 .

Dual treatment of acromegaly and hormone-receptor-positive breast cancer with tamoxifen: a case report

N. Ganji, Jessica D Abramowitz, Sasan Mirfakhraee, 2021, Journal of Medical Case Reports.

Discovery of a first-in-class Aurora A covalent inhibitor for the treatment of triple negative breast cancer.

G. Lu, Bin Zhang, A. Chan, 2023, European journal of medicinal chemistry.

Abstract P6-18-07: Ribociclib + endocrine therapy in patients with hormone receptor-positive, HER2-negative advanced breast cancer presenting with visceral metastases: Subgroup analysis of phase III MONALEESA trials

F. Esteva, Y. Yap, T. Bachelot, 2019, Poster Session Abstracts.